Russell Investments Group Ltd. Sells 10,446 Shares of Fate Therapeutics, Inc. $FATE

Russell Investments Group Ltd. lessened its holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) by 11.6% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 79,377 shares of the biopharmaceutical company’s stock after selling 10,446 shares during the quarter. Russell Investments Group Ltd. owned 0.07% of Fate Therapeutics worth $63,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Graham Capital Management L.P. bought a new position in shares of Fate Therapeutics during the fourth quarter valued at about $37,000. Brevan Howard Capital Management LP bought a new stake in shares of Fate Therapeutics in the 4th quarter valued at about $41,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Fate Therapeutics during the 4th quarter valued at about $55,000. ProShare Advisors LLC boosted its holdings in Fate Therapeutics by 77.9% during the 4th quarter. ProShare Advisors LLC now owns 33,645 shares of the biopharmaceutical company’s stock valued at $56,000 after acquiring an additional 14,728 shares during the period. Finally, Squarepoint Ops LLC grew its position in Fate Therapeutics by 154.2% during the 4th quarter. Squarepoint Ops LLC now owns 34,295 shares of the biopharmaceutical company’s stock worth $57,000 after acquiring an additional 20,805 shares during the last quarter. 97.54% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Wall Street Zen upgraded Fate Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, August 18th. Robert W. Baird dropped their target price on shares of Fate Therapeutics from $5.00 to $4.00 and set a “neutral” rating for the company in a report on Wednesday, May 14th. Wells Fargo & Company lowered their price target on Fate Therapeutics from $4.00 to $2.50 and set an “equal weight” rating for the company in a research report on Wednesday, August 13th. Barclays dropped their price objective on Fate Therapeutics from $10.00 to $2.00 and set an “overweight” rating for the company in a report on Wednesday, May 14th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Fate Therapeutics in a research note on Thursday, June 12th. One investment analyst has rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $3.30.

Fate Therapeutics Stock Down 3.0%

NASDAQ FATE opened at $0.97 on Friday. The firm has a market capitalization of $111.87 million, a PE ratio of -0.67 and a beta of 2.21. The stock’s 50 day moving average is $1.11 and its 200 day moving average is $1.12. Fate Therapeutics, Inc. has a twelve month low of $0.66 and a twelve month high of $4.20.

Fate Therapeutics (NASDAQ:FATE) last posted its quarterly earnings data on Tuesday, August 12th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.06. The business had revenue of $1.91 million during the quarter, compared to the consensus estimate of $1.16 million. Fate Therapeutics had a negative return on equity of 50.95% and a negative net margin of 2,025.05%. On average, research analysts anticipate that Fate Therapeutics, Inc. will post -1.63 earnings per share for the current year.

Fate Therapeutics Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.